Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2024, 6(7); doi: 10.25236/FMSR.2024.060709.

Performance Evaluation of HBV-DNA Detection by ABI7500 Polmerase Chain Reactor and Analysis of Anti-interference Ability

Author(s)

Haiyan Zhang1, Jian Dong2

Corresponding Author:
Jian Dong
Affiliation(s)

1Research Center, Department of Basic Medicine, Zhangzhou Health Vocational College, Zhangzhou, Fujian, 363000, China

2Laboratory Department, 909th Hospital of Zhangzhou (Southeast Hospital Affiliated to Xiamen University), Zhangzhou, Fujian, 363000, China

Abstract

The aim of this paper is to evaluate the performance of ABI7500 HBV-DNA detecting system to determine whether the system meets the clinical detection requirements. Referring to the document CNAS-CL02-A009: 2018 of the National Accreditation Committee for Conformity Assessment, the application of the accreditation criteria for quality and competence of medical laboratories in the field of molecular diagnosis, the in-batch precision, inter-batch precision, accuracy, linear range and anti-interference ability of the detection system were evaluated. The precision of the system is less than 3/5TEa in batch and 4/5TEa between batches. Correctness is good. The linearity of the system is good in the range of 2.61×102-2.61×108 copies/ml. The results of high and median serum tests are not easily interfered by three substances: bilirubin, hemoglobin and triglyceride. The low-value serum tests are more susceptible to the interference of these three substances. The ABI7500 HBV-DNA detection system has good performance evaluation results and can meet the requirements of clinical detection.

Keywords

HBV-DNA; ABI7500; precision; correctness; linearity; interference test

Cite This Paper

Haiyan Zhang, Jian Dong. Performance Evaluation of HBV-DNA Detection by ABI7500 Polmerase Chain Reactor and Analysis of Anti-interference Ability. Frontiers in Medical Science Research (2024), Vol. 6, Issue 7: 77-83. https://doi.org/10.25236/FMSR.2024.060709.

References

[1] Marcellin P, Bonino F, Yurgaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013; 7(1): 88-97.

[2] Kaplan DE. Immunopathogenesis of Hepatitis C virus infection. Gastroenterol Clin North Am. 2015; 44(4):735-760.

[3] Ma Liling, Xu Junchi, Wu Minjuan, et al. The relationship between HBV-DNA and serum markers of hepatitis B. Jiangsu Medical Journal. 2018;44(11):1279-1282.

[4] Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-475.

[5] Meng Bin, Zhang Haoliang, Li Shibao, Zhao Yao, Ma Ping. Performance and evaluation of a real-time fluorescent quantitative PCR detection kit for Epstein-Barr virus DNA. Journal of Clinical and Pathology. 2018;38(5):929-935.

[6] Wang Jiao, Qian Jun, Shi Ying, et al. Performance validation of the Mx3000pTM real-time fluorescent quantitative PCR system for HBV-DNA detection. China Medical Herald. 2018;15(15):65-68.

[7] Cao Xiu'e, Luan Fang, Liu Yiqing, et al. Performance study of the Biosystems BA400 automatic specific protein analyzer in detecting urinary transferrin. Medical Health Equipment. 2019;40(4):40-43, 51.

[8] Wang Simin, Wang Yina. Performance validation of the MAGLUMI 2000 automatic chemiluminescence immunoassay analyzer for PCT detection. Medical Health Equipment. 2018; 39(10): 43-46, 49.

[9] Zhang Yunhong, Qin Weichao, He Ling, et al. Validation of the linear range and minimum detection limit of HBV DNA by real-time fluorescent quantitative PCR. International Journal of Laboratory Medicine. 2014;35(17):2362-2363, 2366.

[10] Yu Qing, Teng Fengmeng, Yang Xuewen. The effect of serum bilirubin levels on HBV-DNA detection and methods to eliminate the influence of bilirubin. Laboratory Medicine and Clinic. 2019;16(7):909-911.

[11] Dai Wei, Chen Jian, Zhu Kai, et al. Comparison of three dissociation tests in the detection of neonatal ABO hemolytic disease. Chinese Journal of Blood Transfusion. 2011;24(2):128-129.

[12] Liu Xiaomin, Tang Hengfeng, Li Wenlang, et al. The effect of hyperlipidemia and hemolysis samples on the determination of low-level HBV-DNA by fluorescence quantitative PCR. Laboratory Medicine and Clinic. 2015;12(21):3217-3218, 3220.